GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sinovac Biotech Ltd (NAS:SVA) » Definitions » Cyclically Adjusted FCF per Share

Sinovac Biotech (Sinovac Biotech) Cyclically Adjusted FCF per Share : $12.38 (As of Jun. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Sinovac Biotech Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Sinovac Biotech's adjusted free cash flow per share data for the fiscal year that ended in Dec. 2022 was $-10.284. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $12.38 for the trailing ten years ended in Dec. 2022.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Sinovac Biotech was 45.00% per year. The lowest was -31.00% per year. And the median was -0.10% per year.

As of today (2024-05-01), Sinovac Biotech's current stock price is $ 6.47. Sinovac Biotech's Cyclically Adjusted FCF per Share for the fiscal year that ended in Dec. 2022 was $12.38. Sinovac Biotech's Cyclically Adjusted Price-to-FCF of today is 0.52.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Sinovac Biotech was 24.88. The lowest was 0.49. And the median was 0.52.


Sinovac Biotech Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Sinovac Biotech's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinovac Biotech Cyclically Adjusted FCF per Share Chart

Sinovac Biotech Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.03 -0.14 0.26 13.10 12.38

Sinovac Biotech Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 13.10 - 12.38 -

Competitive Comparison of Sinovac Biotech's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Sinovac Biotech's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sinovac Biotech's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sinovac Biotech's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Sinovac Biotech's Cyclically Adjusted Price-to-FCF falls into.



Sinovac Biotech Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Sinovac Biotech's adjusted Free Cash Flow per Share data for the fiscal year that ended in Dec. 2022 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share /CPI of Dec. 2022 (Change)*Current CPI (Dec. 2022)
=-10.284/115.1156*115.1156
=-10.284

Current CPI (Dec. 2022) = 115.1156.

Sinovac Biotech Annual Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201312 0.008 97.624 0.009
201412 -0.375 99.000 -0.436
201512 -0.019 100.600 -0.022
201612 -0.466 102.600 -0.523
201712 0.838 104.500 0.923
201812 0.036 106.500 0.039
201912 0.259 111.200 0.268
202012 3.094 111.500 3.194
202112 128.349 113.108 130.627
202212 -10.284 115.116 -10.284

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Sinovac Biotech  (NAS:SVA) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Sinovac Biotech's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=6.47/12.38
=0.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Sinovac Biotech was 24.88. The lowest was 0.49. And the median was 0.52.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Sinovac Biotech Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Sinovac Biotech's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Sinovac Biotech (Sinovac Biotech) Business Description

Industry
Traded in Other Exchanges
N/A
Address
No.39, Shangdi Xi Road, Haidan District, Beijing, CHN, 100085
Sinovac Biotech Ltd is a biopharmaceutical company. The company focuses on the research, development, manufacturing, and commercialization of vaccines for infectious diseases. Its product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps, and canine rabies. The company also provides services for disease control and prevention, collaborating with the Chinese governments at the national, state, and local levels. It sells its vaccines in China, while also exploring growth opportunities in international markets.
Executives
Lily Wang director, 10 percent owner, officer: Chief Financial Officer 300 MURCHISON DR., MILLBRAE CA 94030
Ifg Investments Services Inc 10 percent owner PO BOX 822, CHARLESTOWN FEDERATION OF ST KITTS & NEVIS WEST INDIES P8 00000
Yin Weidong director, 10 percent owner, officer: President and CEO
Terry G Bowering director, 10 percent owner, officer: President, CEO 10 CEDAR MEADOW DRIVE REGINA A9 S4X 3J6

Sinovac Biotech (Sinovac Biotech) Headlines

From GuruFocus

SINOVAC COVID-19 Vaccine Is Conditionally Registered In South Africa

By Business Wire Business Wire 06-25-2022

SINOVAC Varicella Vaccine Prequalified by WHO

By Business Wire Business Wire 11-04-2022